The use of selective monoamine oxidase inhibitor drugs to modify amine metabolism in brain.
D000818:Animals; D001593:Benzyl Compounds; D001665:Binding Sites; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000201:enzymology*; D002499:Centrifugation, Density Gradient; D005615:Freezing; D007527:Isoenzymes / Q000302:isolation & purification / Q000378:metabolism; D007700:Kinetics; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D008995:Monoamine Oxidase / Q000302:isolation & purification / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009638:Norepinephrine; D009647:Normetanephrine; D010627:Phenethylamines; D011485:Protein Binding; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D012701:Serotonin; D013329:Structure-Activity Relationship; D013997:Time Factors
D001593:Benzyl Compounds; D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D009647:Normetanephrine; D012701:Serotonin; D012110:Reserpine; D008995:Monoamine Oxidase; D009638:Norepinephrine